However, some showed promising results, and, as opposed to strategies aiming at destroying the tumor microenvironment (PEGPH or CAF depletion), those encouraging trials are aimed at reprogramming CAFs into non-activated cells (ATRA or vitamin D), or “normalizing” the stroma by targeting signaling pathways involved in its pro-tumor features (SOM230 or FAK inhibitors) (Figure 2). Here, PTK2 is linked to neoplasm.